Kunihiko Kobayashi

Saitama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 249 publications

DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer.

DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Comparison of anthracycline plus platinum versus other platinum-based regimens as first-line chemotherapy for untreated thymoma: A retrospective cohort study (NEJ023B).

Comparison of anthracycline plus platinum versus other platinum-based regimens as first-line chemotherapy for untreated thymoma: A retrospective cohort study (NEJ023B).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 29, 2026

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.

Journal: The New England journal of medicine

Published: October 17, 2025

Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 11, 2025

Cultural Adaptation and Preliminary Validation of Adherence Questionnaires for Japanese Patients with Breast Cancer: A Pilot Study.

Cultural Adaptation and Preliminary Validation of Adherence Questionnaires for Japanese Patients with Breast Cancer: A Pilot Study.

Journal: Patient preference and adherence

Published: July 11, 2025

Lung immune prognostic index as a biomarker for predicting the benefit of immune checkpoint inhibitor plus chemotherapy in older patients with non-small cell lung cancer: a secondary analysis of the NEJ057 study.

Lung immune prognostic index as a biomarker for predicting the benefit of immune checkpoint inhibitor plus chemotherapy in older patients with non-small cell lung cancer: a secondary analysis of the NEJ057 study.

Journal: International journal of clinical oncology

Published: May 03, 2025

A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2).

A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2).

Journal: Clinical lung cancer

Published: May 01, 2025

A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study.

A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 26, 2025

Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial.

Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial.

Journal: The Lancet. Respiratory medicine

Published: April 08, 2025

Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study.

Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study.

Journal: Medicina (Kaunas, Lithuania)

Published: March 21, 2025

A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer.

A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer.

Journal: Future oncology (London, England)

Published: March 07, 2025

Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapy.

Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapy.

Journal: Scientific reports

Published: February 26, 2025

Showing 1-12 of 249

Last Updated: 09/26/2026